Safety and Effectiveness of Endoscopist-Directed Nurse-Administered Sedation during Gastric Endoscopic Submucosal Dissection
Table 1
Clinical characteristics of the patients.
M group ()
MP group ()
value
Age (yr)
68 ± 10.2
66.2 ± 10.0
0.206
Gender, n (%)
0.458
Male
53 (63.9)
74 (58.7)
Female
30 (36.1)
52 (41.3)
Body mass index (kg/m2)
24.6 ± 3.8
24.9 ± 3.0
0.619
Smoking history, n (%)
0.229
Nonsmoker
63 (75.9)
95 (75.4)
Ex-smoker
12 (14.5)
11 (8.7)
Current smoker
8 (9.6)
20 (15.9)
Alcohol abuse, n (%)
11 (13.3)
15 (11.9)
0.773
Use of antiplatelet agents, n (%)a
22 (26.5)
22 (17.5)
0.117
Regular use of sedatives or psychotrophic drugs, n (%)
4 (4.8)
4 (3.2)
0.544
Midazolam dose, mg
5.8 ± 1.9
5.5 ± 1.6
0.228
Propofol dose, mg
—
91.5 ± 72.9
Antihypertensive agent administration, n (%)
1 (1.2)
4 (3.2)
0.65
ASA physical status, n (%)
0.692
1
20 (24.1)
37 (29.4)
2
43 (51.8)
62 (49.2)
3
20 (24.1)
27 (21.4)
Values are mean ± SD or n (%) of patients. aAntiplatelet agents include aspirin, nonsteroidal anti-inflammatory drugs, and plavix. These medications were discontinued in all patients prior to endoscopic submucosal dissection. SD: standard deviation; M: sedation with midazolam; MP: sedation with midazolam plus intermittent propofol injection; ASA: American Society of Anesthesiologists.
